Money Talks Louder To Sirtex As Varian Gets Ditched
Executive Summary
Sirtex Medical has accepted the acquisition bid from the owners of CDH Genetech for Aus $33.60 per share, or $1.41bn, that was first announced in May. In January, Varian signed a deal to acquire Sirtex for Aus$28 per share ($1.28bn), but decided not to match CDH's bid, and Sirtex's board decided the higher sale price was worth the additional uncertainties that come with accepting the offer.
You may also be interested in...
M&A Analysis: Dealmaking Simmers In June
Medtech M&A activity waned in June, with the market showing signs of a summer slump. Twelve acquisitions were announced and closed during the month, a dip in activity compared to the 21 deals recorded in the same period last year, and the 17 recorded in May.
Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?
Varian Medical Systems' proposed $1.3bn deal to acquire SirTex Medical is officially in jeopardy after China's CDH Investments formalized its rival bid to snatch away the Australian interventional oncology firm. Should the deal fall through, what would Varian's next steps be?
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.